UPELRI royalty stream valued at $525M
The thesis presented: Theravance's 35% economic interest in the COPD drug UPELRI is worth ~$525M in a DCF, representing the core value driver beyond cash.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.